We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.7B
AUM Growth
-$152M
Cap. Flow
+$293M
Cap. Flow %
3.03%
Top 10 Hldgs %
29.73%
Holding
234
New
14
Increased
60
Reduced
64
Closed
43

Top Buys

Rank Stock Value
1
CDNA icon
CareDx
CDNA
+$74.9M
2
ABT icon
Abbott
ABT
+$45.9M
3
MOH icon
Molina Healthcare
MOH
+$43.5M
4
DHR icon
Danaher
DHR
+$42M
5
MDT icon
Medtronic
MDT
+$38M

Top Sells

Rank Stock Value
1
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$63.1M
2
BAX icon
Baxter International
BAX
+$38.1M
3
CNC icon
Centene
CNC
+$36.2M
4
HOLX
Hologic
HOLX
+$21.4M
5
DXCM icon
DexCom
DXCM
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.85%
2 Technology 0.8%
3 Industrials 0.75%
4 Communication Services 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRMY icon
126
Harmony Biosciences
HRMY
$2.04B
$5.17M 0.05%
121,161
-8,128
-6% -$324K
NPCE icon
127
Neuropace
NPCE
$505M
$5.12M 0.05%
507,930
– –
BNR
128
Burning Rock Biotech
BNR
$4.67M 0.05%
48,989
– –
GTH
129
DELISTED
Genetron Holdings Limited ADS
GTH
$4.41M 0.05%
241,046
– –
PRCT icon
130
Procept Biorobotics
PRCT
$950M
$4.34M 0.04%
173,649
+23,649
+16% +$875K
OLK
131
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$4.28M 0.04%
235,273
+37,746
+19% +$931K
RCUS icon
132
Arcus Biosciences
RCUS
$3.57B
$3.54M 0.04%
87,500
-7,200
-8% -$279K
JNJ icon
133
Johnson & Johnson
JNJ
$635B
$3.46M 0.04%
20,200
-10,300
-34% -$1.69M
AZN icon
134
AstraZeneca
AZN
$263B
$3.44M 0.04%
+29,500
New +$3.47M
BCYC
135
Bicycle Therapeutics
BCYC
$270M
$3.27M 0.03%
53,700
-12,000
-18% -$662K
MRTX
136
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.17M 0.03%
21,600
+2,700
+14% +$419K
KYMR icon
137
Kymera Therapeutics
KYMR
$9.1B
$3.11M 0.03%
49,000
+13,500
+38% +$786K
SEER icon
138
Seer Inc
SEER
$108M
$3.1M 0.03%
136,133
– –
CTLT
139
DELISTED
CATALENT, INC.
CTLT
$2.96M 0.03%
23,100
-12,900
-36% -$1.66M
BPMC
140
DELISTED
Blueprint Medicines
BPMC
$2.73M 0.03%
+25,500
New +$2.67M
LH icon
141
Labcorp
LH
$24.3B
$2.65M 0.03%
9,836
-41,496
-81% -$10.3M
DGX icon
142
Quest Diagnostics
DGX
$25.1B
$2.64M 0.03%
15,250
+2,250
+17% +$342K
SYNH
143
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$2.21M 0.02%
21,500
-35,500
-62% -$3.41M
INBX
144
DELISTED
Inhibrx, Inc. Common Stock
INBX
$2.21M 0.02%
+50,500
New +$2.02M
XNCR icon
145
Xencor
XNCR
$1.44B
$2.09M 0.02%
52,100
– –
LLY icon
146
Eli Lilly
LLY
$1.07T
$2.09M 0.02%
+7,552
New +$1.91M
NTLA icon
147
Intellia Therapeutics
NTLA
$1.5B
$1.96M 0.02%
16,594
– –
RARE icon
148
Ultragenyx Pharmaceutical
RARE
$2.65B
$1.77M 0.02%
21,000
-6,900
-25% -$561K
ZTS icon
149
Zoetis
ZTS
$31.6B
$1.73M 0.02%
7,100
– –
ARCT icon
150
Arcturus Therapeutics
ARCT
$157M
$1.54M 0.02%
41,600
+7,100
+21% +$289K
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2021 Portfolio in Review

As of Q4 2021, Bellevue Group held 234 positions worth $9.7B, down 1.5% from $9.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group deployed $293M of net new capital in Q4 2021, opening 14 new positions and adding to 60 existing holdings. Its largest new stake was AstraZeneca: 29,500 shares worth $3.44M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Baxter International, an estimated $38.1M trimmed.

  • Bellevue Group's largest Q4 2021 buy was AstraZeneca: 29,500 shares worth $3.44M.
  • Bellevue Group added most to CareDx in Q4 2021, an estimated $74.9M increase.
  • Bellevue Group's biggest Q4 2021 reduction was Baxter International, cutting an estimated $38.1M.
  • Bellevue Group fully exited HILL-ROM HOLDINGS, INC. in Q4 2021, selling an estimated $63.1M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.7B portfolio in Q4 2021.
  • Bellevue Group opened 14 new positions and closed 43 in Q4 2021.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $9.7B.

Based on Bellevue Group's 13F filing for Q4 2021, filed 10 Feb 2022.